- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00738829
Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLL
Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide Followed by Rituximab/Lenalidomide in Untreated Chronic Lymphocytic Leukemia (CLL) - a Dose-finding Study With Concomitant Evaluation of Safety and Efficacy.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Feldkirch, Austria, A-6806
- Landeskrankenhaus Feldkirch
-
Linz, Austria, A-4010
- Krankenhaus der Elisabethinen Linz GmbH
-
Linz, Austria, A-4010
- Krankenhaus d. Barmherzigen Schwestern Linz
-
Linz, Austria, A-4020
- Krankenhaus der Stadt Linz
-
Salzburg, Austria, A-5020
- Universitaetsklinik f. Innere Medizin III
-
Wels, Austria, A-4600
- Klinikum Wels-Grieskirchen GmbH
-
-
Tirol
-
Innsbruck, Tirol, Austria, A-6020
- Medizinische Universitaet Innsbruck, Abtlg. f. Haematologie und Onkologie
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- B-CLL (CD23+, CD5+, CD19+, CD20+)
- Treatment indication according to NCI criteria
- Age >= 18 yrs
- No previous treatment of CLL by chemo-, radio- or immunotherapy
- Life expectancy > 6 months
- Written informed consent
- Women of non-childbearing potential or women of childbearing potential and men using effective contraception
Exclusion Criteria:
- Active bacterial, viral or fungal infection
- Positivity for HIV, Hepatitis B or C
- Reduce organ functions and bone marrow dysfunction not due to CLL
- Creatinine clearance below 30 ml/min
- Patients with medical conditions requiring long-term use of systemic corticosteroids during study treatment
- Patients with a history of severe cardiac disease
- Other known co-morbidity with the potential to dominate survival
- Transformation to aggressive B-cell malignancy
- Known hypersensitivity to humanised monoclonal antibodies or any of the study drugs
- Pregnant or breast-feeding women
- Any co-existing medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Treatment Arm
Lenalidomide Dose Escalation combined with Fludarabine/Rituximab followed by maximum tolerated lenalidomide dose/Rituximab maintenance therapy
|
Dose escalation stage: starting dose 2.5mg/d, dose escalation via 5/10/15/20/25 mg/d every 28 days if no dose-limiting toxicity. During maintenance stage dosing on days 1-28 for max. 6 months at maximum tolerated dose reached during dose escalation stage.
Other Names:
25 mg/m2 i.v.
d1-3 or 40 mg/m2 po d1-3 every 28 days for 6 cycles during dose escalation stage.
Other Names:
Dose escalation stage: 375 mg/m2 i.v. d4 Cycle 1, 500 mg/m2 i.v. d1 Cycles 2-6. Maintenance stage: 375 mg/m2 i.v. at 2/4/6 months after end of escalation stage.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Lenalidomide Maximum Tolerated Dose
Time Frame: Dose escalation stage
|
Dose escalation stage
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety profile of Lenalidomide/Fludarabine/Rituximab treatment
Time Frame: Study Duration
|
Study Duration
|
Safety Profile of Lenalidomide/Rituximab
Time Frame: Study duration
|
Study duration
|
Response rate for Lenalidomide/Fludarabine/Rituximab combination treatment
Time Frame: Dose escalation stage
|
Dose escalation stage
|
Response rate for Lenalidomide/Rituximab combination therapy
Time Frame: Study Duration
|
Study Duration
|
Response rate by 4-colour flow cytometric MRD analysis
Time Frame: Study Duration
|
Study Duration
|
Changes in Quality of Life scores
Time Frame: Study Duration
|
Study Duration
|
Risk factors and clonal evolution
Time Frame: Study Duration
|
Study Duration
|
Collaborators and Investigators
Investigators
- Principal Investigator: Richard Greil, Prof. Dr., Universitaetsklinik f. Innere Medizin III, Universitaetsklinikum der PMU, Salzburg
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Leukemia, B-Cell
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Lenalidomide
- Rituximab
- Fludarabine
- Fludarabine phosphate
Other Study ID Numbers
- CLL-5
- EudraCT Nr. 2008-001430-27
- ML21718
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Leukemia, Lymphocytic, Chronic, B-Cell
-
National Heart, Lung, and Blood Institute (NHLBI)Active, not recruitingLeukemia, Lymphocytic, Chronic, B-Cell | Chronic Lymphocytic Leukemia | Leukemia, Chronic Lymphatic | B-Cell Chronic Lymphocytic Leukemia | Leukemia, Lymphocytic, Chronic | B-Lymphocytic Leukemia, Chronic | Leukemia, Chronic Lymphocytic, B-Cell | Lymphocytic Leukemia, Chronic, B Cell | Lymphocytic Leukemia...United States
-
National Cancer Institute (NCI)CompletedB-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic LeukemiaUnited States
-
Fred Hutchinson Cancer Research Center/University...WithdrawnB-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia
-
French Innovative Leukemia OrganisationTerminatedB-cell Chronic Lymphocytic Leukemia (B-CLL)France
-
Genzyme, a Sanofi CompanyBayer Healthcare Pharmaceuticals, Inc./Bayer Schering PharmaCompletedB-Cell Chronic Lymphocytic Leukemia (B-CLL)United Kingdom, Belgium, France, United States, Czech Republic, Serbia
-
Shanghai Zhangjiang Biotechnology Limited CompanySuspendedB-cell Chronic Lymphocytic LeukemiaChina
-
Mundipharma Research LimitedTerminatedB-cell Chronic Lymphocytic LeukemiaSpain
-
CelgeneCompletedB-cell Chronic Lymphocytic LeukemiaUnited States, Spain, United Kingdom, Canada, Belgium, Czechia, Hungary, Italy, Poland, Israel, Germany, Ireland, France, New Zealand, Denmark, Australia, Netherlands, Romania, Russian Federation, Sweden, Austria, South Africa, Colo... and more
-
French Innovative Leukemia OrganisationRoche Pharma AGCompletedB-cell Chronic Lymphocytic Leukemia CLLFrance
-
OnxeoCompletedB-cell Chronic Lymphocytic LeukemiaUnited Kingdom
Clinical Trials on Lenalidomide
-
Sidney Kimmel Comprehensive Cancer Center at Johns...TerminatedMyelodysplastic SyndromeUnited States
-
Grupo Español de Linfomas y Transplante Autólogo...Celgene Corporation; Dynamic Science S.L.; Thermo Fisher Scientific, IncCompleted
-
Celgene CorporationICON Clinical ResearchCompletedMyelodysplastic SyndromesGermany, Israel, United Kingdom, Spain, Belgium, Italy, France, Netherlands, Sweden
-
Swiss Group for Clinical Cancer ResearchTerminatedLymphomaSwitzerland, Norway, Sweden
-
Boston VA Research Institute, Inc.Celgene Corporation; Edward Hines Jr. VA Hospital; Michael E. DeBakey VA Medical... and other collaboratorsCompletedMultiple MyelomaUnited States
-
Dana-Farber Cancer InstituteBeth Israel Deaconess Medical Center; Genentech, Inc.; Brigham and Women's Hospital and other collaboratorsTerminatedWaldenstrom's MacroglobulinemiaUnited States
-
University Hospital, ToulouseCelgene Corporation; Janssen-Cilag Ltd.Completed
-
CelgeneCompletedRelapsed or Refractory Chronic Lymphocytic LeukemiaUnited States, Canada, United Kingdom, France, Germany, Spain, Italy, Sweden
-
Groupe Francophone des MyelodysplasiesUnknownMyelodysplastic SyndromesFrance